Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is inviting research applications for the "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)" funding opportunity. This initiative aims to support the preclinical development of lead candidate vaccines against Mycobacterium tuberculosis (Mtb), focusing on projects that demonstrate substantial investment from industry participants and have existing proof-of-concept data. The funding is critical for expanding the clinical pipeline of viable vaccine candidates, with an anticipated total commitment of $4.73 million for FY 2026, allowing for 4-5 awards, each with a maximum budget of $750,000 in direct costs per year over five years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by November 7, 2025.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.